{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:45:32Z","timestamp":1776685532751,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejso.2020.06.034","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:07:23Z","timestamp":1592946443000},"page":"e33-e39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"PB","title":["Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-524X","authenticated-orcid":false,"given":"Zhening","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2020.06.034_bib1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O Neil","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejso.2020.06.034_bib4","first-page":"19","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: Keynote-164","author":"Le","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib5","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II Keynote-158 study","author":"Marabelle","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib7","doi-asserted-by":"crossref","first-page":"A4007","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA4007","article-title":"Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study","volume":"37","author":"Tabernero","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib10","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3389\/fonc.2019.00396","article-title":"Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer","volume":"9","author":"Oliveira","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib14","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejso.2020.06.034_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581547","article-title":"Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis","volume":"8","author":"Chen","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejso.2020.06.034_bib17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib18","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2019.37.15_suppl.3504","article-title":"FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer","volume":"37","author":"Seymour","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96836","article-title":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","volume":"3","author":"Markowitz","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejso.2020.06.034_bib20","first-page":"2019","article-title":"Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor-antigen specific T cells","volume":"26","author":"Friedman","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2020.06.034_bib21","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4049\/jimmunol.1700643","article-title":"PD-1 blockade promotes epitope spreading in anticancer CD8+ T cell responses by preventing fratricidal death of subdominant clones to relieve immunodomination","volume":"199","author":"Memarnejadian","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ejso.2020.06.034_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejso.2020.06.034_bib23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2159-8290.CD-16-1109","article-title":"Making the most of cancer surgery with neoadjuvant immunotherapy","volume":"6","author":"Melero","year":"2016","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejso.2020.06.034_bib24","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1158\/0008-5472.CAN-05-0328","article-title":"Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy","volume":"65","author":"Broomfield","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2020.06.034_bib25","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treatment","volume":"25","author":"O\u2019Donnell","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2020.06.034_bib26","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejso.2020.06.034_bib27","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1200\/JCO.2018.36.15_suppl.8541","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3)","volume":"36","author":"Rusch","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib28","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2019.37.15_suppl.8504","article-title":"Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and correlative results from the NEOSTAR study","volume":"37","author":"Cascone","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib29","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2018.36.15_suppl.8521","article-title":"Neoadjuvant chemo\/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): a phase II multicenter exploratory study-NADIM study-SLCG","volume":"36","author":"Provencio-Pulla","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib30","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2019.37.15_suppl.9013","article-title":"Keynote-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC","volume":"37","author":"Gadgeel","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib31","doi-asserted-by":"crossref","first-page":"v918","DOI":"10.1093\/annonc\/mdz394.080","article-title":"LBA82 Pembrolizumab (pembro)\u00a0+ chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in Keynote-407","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib32","doi-asserted-by":"crossref","first-page":"9084","DOI":"10.1200\/JCO.2017.35.15_suppl.9084","article-title":"Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"35","author":"Leger","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib33","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/JCO.2017.35.15_suppl.9000","article-title":"Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) \u226550% enrolled in KEYNOTE-024","volume":"35","author":"Brahmer","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2020.06.034_bib35","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.ejso.2020.06.034_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.ejso.2020.06.034_bib37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib38","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/1078-0432.CCR-19-1372","article-title":"Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade","volume":"25","author":"Georgiadis","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2020.06.034_bib39","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib40","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.06.034_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581530","article-title":"Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome","volume":"8","author":"Liu","year":"2019","journal-title":"OncoImmunology"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832030559X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832030559X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:33:47Z","timestamp":1760060027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832030559X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S074879832030559X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2020.06.034","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2020.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}